We studied the activation pattern of clotting, fibrinolysis, and kinin-kallikrein during the first 5 d of life in 10 preterm infants with signs of severe idiopathic respiratory distress syndrome (IRDS) after birth (IRDS group) and in 12 healthy preterm infants (reference group). We found systemic activation of clotting, fibrinolysis, and kininkallikrein in the IRDS infants within 12 to 24 h of birth, represented by increased median thrombin-antithrombin I11 complex formation (90 ng/mL versus 10 ng/mL in the reference group, p < 0.05), increased mean tissue-type plasminogen activator plasma concentrations (11.8 ng/mL versus 3.5 ng/mL in the reference group, p < 0.05), and increased mean plasma kallikrein activity (182.6% versus 162.0% of maximal activated human plasma in the reference group,p < 0.05), respectively. Clotting activation was accompanied by a significant decrease of the platelet count. Clotting and fibrinolytic activity decreased in the IRDS group during the first 2 to 3 d of life. Kinin-kallikrein activation was accompanied by decreased plasma kallikrein inhibitor activity values and did not change throughout the study period. Plasma factor XI1 activity was not significantly increased in the IRDS infants during the first 2 d of life but did significantly increase thereafter. The cause of simultaneous activation of clotting, fibrinolysis, and kinin-kallikrein in our IRDS infants has not yet been clarified. However, this activation process may contribute to lung injury such as that described in the adult respiratory distress syndrome.(Pediatr Res 36: 647-653, 1994) Abbreviations IRDS, idiopathic respiratory distress syndrome CPP, cryoglobulin poor plasma AT 111, antithrombin 111 T-AT 111, thrombin-antithrombin I11 F XIIa, factor XI1 activity t-PA, tissue-type plasminogen activator PKKI, plasma kallikrein inhibitor activity % AHP, percentage of maximal activated human plasma % NHP, percentage of normal human plasma Intraalveolar and intravascular deposition of fibrin has been found in preterm infants suffering from IRDS (1, 2). These fibrin depositions are likely to contribute to respiratory insufficiency. Intraalveolar fibrin, a major component of hyaline membranes, inactivates considerable amounts of surfactant (1-3). Intravascular fibrin, found at autopsy in the lungs of preterm infants who died of severe IRDS, decreases surfactant synthesis due to impaired lung perfusion (1, 2). These intraalveolar and intravascular fibrin depositions are the result of activation of the clotting system represented
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We hypothesized that similar simultaneous activation of plasma protein systems occurs in the first days of life in preterm infants with respiratory insufficiency due to IRDS. Therefore, we studied the activation pattern of different components of the clotting, fibrinolytic, and kinin system during the first 5 d of life in preterm infants with respiratory failure from birth and with clinical and radiologic signs of IRDS.
METHODS

Patients.
The study included 22 preterm infants who were consecutively admitted to the neonatal intensive care unit of the Beatrix Childrens Hospital, University Hospital of Groningen, between October 1, 1992 and January 1, 1993. These infants were born in the Department of Obstetrics of the University Hospital of Groningen and met the following criteria for enrollment: 1 ) gestational age between 28 and 33 wk; 2) birth weight appropriate for gestational age; and 3 ) no major congenital malformations or evidence of infection. Ten infants showed clinical and radiologic signs of severe IRDS, ventilatory dependency, and oxygen requirement of more than 30% for adequate oxygenation (IRDS group). Twelve healthy preterm infants served as a reference group. The study was approved by the medical ethical committee of the University Hospital of Groningen. Informed consent was given by the parents.
The infants of the IRDS group and the reference group were not different for prenatal factors that may influence the activation pattern of the clotting, fibrinolytic, and kinin-kallikrein systems (Table 1) . Dexamethasone was given to the mothers of three infants in both the IRDS and the reference group before delivery. Dexamethasone is known to have inhibitory effects on the fibrinolytic system (11). However, activation of fibrinolysis in the three IRDS infants whose mothers received dexamethasone could not be distinguished from that in the other IRDS infants, whereas it was practically absent in the three reference infants. No other specific drugs that could influence the activation PROM, premature rupture of membranes; HELLP, the syndrome of hemolysis, elevated liver enzymes, and low platelet count; SVD, spontaneous vaginal delivery; CS, caesarean section. There were no significant differences between the IRDS and the reference group with regard to the prenatal factors.
process investigated in this study, such as anticoagulants or indomethacin, were given to the mothers. Postnatal characteristics of both the IRDS and the reference group are presented in Table 2 . All IRDS infants had birth asphyxia and showed clinical signs of respiratory insufficiency requiring endotracheal intubation and artificial ventilation from birth. Despite low Apgar scores and low arterial umbilical pH values at birth, no organ failure other than respiratory insufficiency existed in these infants.
Patient management. All IRDS infants were artificially ventilated throughout the study period to maintain the arterial Po, between 7.5 and 10.0 kPa and the arterial Pco, between 5.5 and 6.5 kPa. When infants showed clinical signs of respiratory distress, required more than 30% oxygen for adequate oxygenation, and needed artificial ventilation because of respiratory insufficiency, they were eligible for the Dutch Multicenter study "Nedsurf" for surfactant replacement therapy (Alvofact, Boehringer, Ingelheim, Germany). In the Nedsurf study, IRDS infants are prospectively classified according to the roentgenologic severity of the disease using the Giedion score (12). Infants showing Giedion 1 or 2 abnormalities on a chest x-ray were considered to have moderate IRDS, whereas infants with a Giedion 3 or 4 chest x-ray were considered to have severe IRDS. In our study, all infants of the IRDS group had severe IRDS. According to the criteria of the Nedsurf study, eight of the 10 infants of the IRDS group received surfactant (100 mglkg body weight endotracheally). The remaining two infants were not given surfactant because of severe circulatory insufficiency.
Infants of less than 34 wk gestational age with respiratory failure requiring artificial ventilation or continuous positive airway pressure were examined with echocardiography for patency of the ductus arteriosus on the second to fourth day of life. A patent ductus arteriosus was treated with one or two courses (3 times 0.2 mglkg) of i.v. indomethacin (Indocid, Merck Sharpe & Dohme, Haarlem, The Netherlands). In our study, six IRDS infants were treated with indomethacin.
Infants received standard supportive care and transfusions of CPP or packed red Good cells combined with 
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CPP to replace blood that was taken for laboratory tests. The IRDS infants received a mean of three (range one to five) transfusions with packed red blood cells and CPP and a mean of one (range zero to three) transfusion with CPP per infant during the first 5 d of life. These transfusions did not exceed 10% of the calculated blood volume in any 24-h period, except for one IRDS infant who received a total of eight transfusions (four transfusions of CPP with packed red blood cells and four transfusions of CPP without packed red blood cells) during the whole study period. CPP is stored frozen and contains native inactive plasma proteins, whereas packed red blood cells contain only 10-20% plasma, including plasma proteins, which are slightly activated by the processing procedure (13). Therefore, we do not consider these transfusions to influence the results of our study, even in the infant who received a total of eight transfusions.
A venous or arterial umbilical catheter was only inserted after approval of the attending neonatologist. The patency of arterial umbilical catheters was maintained by a continuous infusion of 0.9% NaCl solution containing 3 U/mL heparin at a rate of 0.5-0.7 mL/h. It has been demonstrated that this low-dose heparin infusion does not influence clotting in preterm infants (14). All infants of the IRDS group had a venous umbilical catheter, and six of them also had an arterial umbilical catheter. None of the infants in the reference group received an umbilical catheter.
Study protocol. Blood samples were taken from the venous umbilical catheter (IRDS infants) or were obtained by direct venipuncture (reference infants). For ethical reasons, we were not allowed to insert a venous umbilical catheter into the preterm infants of the reference group who were otherwise healthy and therefore did not require any type of central line. We were aware of the susceptibility of some parameters to sampling errors. We tried to minimize the influence of the different sampling techniques on these parameters. Venous umbilical catheters in the IRDS infants were known to be echographically patent; only blood samples collected after a clean venipuncture with immediate free-flowing blood were used for analysis in the reference group. Furthermore, all samples were immediately collected in soft plastic tubes containing appropriate anticoagulant to prevent activation of blood before processing of the samples.
Blood samples were taken on the first day of life within 12 h of birth, between 12 and 24 h of birth, and on the second, third, fourth, and fifth days of life. The first sample was taken before any medical treatment, including surfactant and administration of indomethacin or blood products, had occurred. Each blood sample was taken during routine blood sampling and used for measuring activation of clotting (platelet count, T-AT 111, F XIIa), fibrinolysis (t-PA), and kinin-kallikrein (kallikrein activity; PKKI). At each sampling, 0.3 m L of blood was taken and anticoagulated with EDTA (0.01 M) for determination of the platelet count; 0.5 m L of blood was anticoagulated with citrate (0.3%) and centrifuged, and the plasma was stored at -70°C until kallikrein activity, PKKI, F XIIa, and plasma concentration of t-PA were determined. Another 0.5 m L of blood was anticoagulated with hirudin-aprotinin and centrifuged, and the plasma was stored at -70°C. T-AT I11 complex was determined in this sample.
Assays. The platelet count was determined using a cell counter (Hemolog, Coulter Electronics, London, UK). F XIIa and kallikrein activity were determined according to a new method using a colorimetric assay (NovaBiochem, Laufelfingen, Switzerland) (15). Both F XIIa and kallikrein activity were expressed as % AHP. PKKI was determined by a colorimetric assay (Kabi Diagnostica, Uppsala, Sweden) and expressed % NHP. T-AT I11 complexes were determined using an enzyme immunoassay (Behring, Marburg, Germany). T-PA was determined by enzyme immunoassay (Kabi Diagnostica).
Statistical analysis. Data are presented as means a SD or as median with 25th and 75th percentiles as appropriate. Gestational age, birth weight, and arterial umbilical pH values in both groups were compared using the unpaired t test; Apgar scores were compared using the Mann-Whitney U test. The X 2 test with Yates' correction for continuity was used for comparison of nominal data.
For F XIIa and T-AT I11 complex, means of six observations were calculated for each individual infant and compared between the IRDS and reference groups using the Mann-Whitney U test; thus, intergroup difference was tested for these parameters. Specific comparison of these values between groups was performed on d 1 (within 12 h of birth) and d 5 using the Mann-Whitney U test. Within groups, the F XIIa and T-AT I11 complex values on d 2,3, 4, and 5 were compared with the values on d 1 (within 12 h of birth) by means of the Wilcoxon signedrank test. For platelet counts, t-PA, kallikrein activity, and PKJSI, statistical analysis was performed with twoway analysis of variance for repeated measures followed by paired or unpaired t tests to determine differences between and within the IRDS and the reference group. Adjustment of the significance level for multiple comparisons was performed according to the Bonferroni correction as appropriate. p values less than 0.05 were considered significant. was significant (1) < 0.05). 'l'hc t-PA plasnla conccntralion dccrcascd significantly from 11.8 + 4.8 ng/mL within 12 h of birth to 5.0 + 2.5 ng/mL on d 5 in the IRDS group ( p < 0.05) and from 3.5 + 3.4 ng/mL to 1.3 + 1.2 ng/mL in the rcfcrcncc group (not significant) (Fig. 4) .
RESULTS
Ventilatory requirements of ZRDS infants.
Kallikrein activity. l'lic plasma kallikrcin activity increased in the IRDS group from 182.6 _+ 39.8% AHP within 12 11 of birth to 207 rt 18.3% AHP o n d 5 (not significant) and dccrcascd in tlic rcfcrcricc group from 162 + 10.6% AHP to 150 + 7.0% AHP (not significant) ( PKKI. PKKI values of the IRDS group were lower than those of the reference group throughout the study period; the difference was significant on d 1 ( p < 0.05). PKKI values in the IRDS group increased significantly from 44 +-10% NHP within 12 h of birth to 60 +-12% NHP on d 5 (p < 0.05). These values increased in the reference group from 61 +-7% NHP within 12 h of birth to 75 2 9% NHP on d 5 (not significant) (Fig. 6 ).
DISCUSSION
In this study, we have found simultaneous activation of the clotting, fibrinolytic, and kinin-kallikrein systems in a group of 10 preterm infants requiring artificial ventilation from birth and with clinical and radiologic signs of IRDS (IRDS group). Clotting and fibrinolytic activity decreased in these infants within the first 2 to 3 d of life. F XIIa increased significantly in the IRDS infants from the third day of life. We observed kallikrein generation accompanied by decreased PKKI throughout the study period.
Activation of the clotting system in the IRDS group was represented by increased T-AT I11 complex plasma concentrations within 12 h of birth. T-AT I11 complex formation is a sensitive marker of thrombin generation (16), which is the key event in clotting. Schmidt et al. (4) have found increased T-AT I11 complex plasma concentrations accompanied by low AT I11 (the main inhibitor of thrombin) plasma concentrations in 3-d-old preterm infants with severe IRDS, which suggests AT I11 consumption due to intravascular clotting. Low AT I11 concentrations, in turn, limit the potential for neutralization of thrombin, the generation of which is maintained in sick preterm newborn infants (17) . Insufficient neutralization leaves thrombin capable of activating platelets and converting fibrinogen to fibrin. After activation by thrombin, platelets aggregate, thus inducing a decrease in the platelet count. We have found a significant decrease of the platelet count in the IRDS infants, which is in accordance with findings of Kohelet et al. (18) . They also reported an association between the severity of the IRDS and the reduction of the platelet count in the first postnatal days. Other authors have demonstrated intravascular formation of fibrin thrombi and deposition of fibrin in hyaline membranes at autopsy in the lungs of preterm infants dying of severe IRDS (1, 2).
We have observed activation of the fibrinolytic system in the group of IRDS infants, which supports the findings of Suzuki (19) . Fibrinolytic activation was represented by significantly higher t-PA plasma concentrations than 652 BRUS ETAL. those in the group of reference infants. Thus, preterm vates factor XI1 (26, 36) , which may explain the increase infants are able to raise t-PA plasma concentrations, as of F XIIa in our IRDS infants from the third day of life. has been demonstrated by Corrigan and Jeter (20) in
In this study, we have shown that during the first 5 d of "stressed" 1-to 29-d-old infants with congenital heart life systemic activation of clotting, fibrinolysis, and kinindisease. In the presence of fibrin, t-PA converts plasmin-kallikrein occurs simultaneously in preterm infants with ogen into plasmin. Plasmin causes lysis of fibrin(ogen) clinical and radiologic signs of IRDS. This activation with formation of fibrin(0gen) degradation products. Process seems to have a two-stage course-Whether this However, plasminogen levels in preterm infants with process is a consequence and IRDS are low (21) . Therefore, fibrinolysis is thought to be due perinatal Or pulmonary tissue insufficient in IRDS infants, which allows intravascular injury due to ongoing artificial ventilation is unknown. fibrin formation and intraalveolar fibrin deposition in However, it may contribute to lung injury in preterm infants with IRDS by intravascular and intraalveolar fithese infants (1, 2).
brin deposition and pulmonary edema formation, as has We have observed in both the IRDS and the reference been described in the adult respiratory distress syndrome group higher kallikrein activity and lower (5-10). However, currently we do not know whether this than in plasma of adults. This may be related to low process is associated with IRDS severity. Timeplasma concentrations of the main kallikrein antiprotease dependent studies in preterm infants with mild, moder-C, esterase (22)-In plasma the IRDS infants, ate, and severe IRDS on the activation of clotting, fibrihowever, we have found higher kallikrein activity and nolysis, and kinin-kallikrein in plasma and its relation to lower PKKI than in plasma the reference the inflammatory process in the lung (38, 39) will further indicating activation of the kinin-kallikrein system in the elucidate the role of this activation process in the patho-IRDS group, which is in agreement with findings of genesis of IRDS. Saugstad et al. (23, 24) . Activation of the kinin-kallikrein system results in the formation of bradykinin (25, 26) .
